You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Navican is hoping to bring some of the genomic testing and related services Intermountain has been offering for three years to the broader cancer community.
A Counsyl study suggests that just half of individuals go through with insurance-mandated pretest genetic counseling, paying out of pocket or canceling the test instead.
This year, the vast majority of assays the Belgian company facilitates will be non-invasive prenatal testing, which it only started offering in 2013.
Under the Color Family Testing Program, family members of patients who tested positive for a gene on Color's hereditary cancer test can be tested for $50.
Backed by $12 million from a recent Series A financing and a strategic partnership with Thermo Fisher Scientific, the Ann Arbor, Michigan-based firm plans to sequence the tumors of 100,000 advanced cancer patients over three years.
In a complaint filed yesterday, Foundation claims that the Guardant360 test infringes its US Patent No. 9,340,830.
The company reported 8,985 clinical tests in the first quarter, a 14 percent year-over-year increase.
Over the last half year, CeGaT lowered turnaround times and prices for its assays, and its lab recently passed CAP inspection.
A year after launching the test in the US, the company is making it available in more than 100 countries, partnering with distributors in Israel, Turkey, and Finland.
Kailos will provide lower-cost screening for hereditary ovarian and peritoneal cancers through Teal It's Gone, a non-profit promoting testing options.
Los Angeles brought and settled a civil enforcement action against the makers of an at-home test for SARS-CoV-2, NPR reports.
The Guardian reports that Cancer Research UK is cutting its research funding by £44 million.
Technology Review examines factors affecting SARS-CoV-2 testing turnaround times.
In PNAS this week: mapping of ancient human migrations in Europe, recurrent gene fusion in breast cancer, and more.